Drug Profile

Ferumoxtran-10 dextran-coated

Alternative Names: AMI 227; AMI 227CN; AMI 27; BMS 180549; Combidex; G 53425; Sinerem

Latest Information Update: 24 Oct 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Advanced Magnetics
Developer AMAG Pharmaceuticals; Guerbet
Class Contrast media; Ferric compounds; Glucans; Oxides
Mechanism of Action Magnetic resonance imaging enhancers

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Discontinued Lymphoma

Most Recent Events

16 Nov 2020 AMAG Pharmaceuticals has been acquired by Covis Pharma
25 Jul 2007 Advanced Magnetics is now called AMAG Pharmaceuticals
28 Feb 2007 Advanced Magnetics and Cytogen agreed to early termination of their licensing agreement, and reached a lawsuit settlement

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com